批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/07/12 |
SUPPL-56(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/12/16 |
SUPPL-50(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/04/02 |
SUPPL-49(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2017/10/18 |
SUPPL-46(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/03/24 |
SUPPL-44(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/09/14 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/04/21 |
SUPPL-43(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/08/18 |
SUPPL-39(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/04/15 |
SUPPL-41(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/07/18 |
SUPPL-38(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/05/01 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/05/01 |
SUPPL-36(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2013/05/01 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/08/10 |
SUPPL-33(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/03/01 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/10/11 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/04/23 |
SUPPL-27(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2006/05/03 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/02/18 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/19 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/10/24 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/08/15 |
SUPPL-10(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2002/01/30 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/01/18 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/04/26 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/10/12 |
SUPPL-5(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2000/09/19 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/03/02 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:GABAPENTIN 剂型/给药途径:SOLUTION;ORAL 规格:250MG/5ML 治疗等效代码:AA
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021129 |
001 |
NDA |
NEURONTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
Yes |
Yes |
AA |
2000/03/02
|
VIATRIS |
078974 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2011/02/18
|
MISSION PHARMACAL |
202024 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2012/03/23
|
AMNEAL PHARMS |
076403 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2012/05/01
|
ACELLA PHARMS LLC |
076672 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2013/07/03
|
TARO |
091286 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2016/03/14
|
BELCHER |
216492 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2023/01/18
|
RUBICON |
217682 |
001 |
ANDA |
GABAPENTIN |
GABAPENTIN |
SOLUTION;ORAL |
250MG/5ML |
Prescription |
No |
No |
AA |
2024/01/17
|
ANNORA PHARMA |